What is ZBIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.04B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ZBIO?

P/E (TTM) is n/a and 52-week range is $13.50 to $44.60 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ZBIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ZBIO?

The company profile lists revenue (TTM) near $997K, net income (TTM) near $-11.12B, EPS (TTM) near $-8.97 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Zenas Biopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 63.1M shares outstanding, ISIN US98937L1052 when available from company profile and filing metadata.

Zenas Biopharma Inc

$ZBIO

Health Care · Biotechnology

Run Scenarios

$27.26

+3.89%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company is headquartered in Waltham, Massachusetts and currently employs 167 full-time employees. The company went IPO on 2024-09-13. The firm's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The firm is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.

Employees

167

Website

zenasbio.com/

IPO

2024-09-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)